Vaccine Development Services: Deadline May 31st, 2022
Developing a vaccine is a time-consuming and complex process, requiring a combination of specialized skills and technical capacities not readily available at a single organization. To enable access to these skills and capacities, TRANSVAC2 offers high-quality technical services to support the development of prophylactic and therapeutic vaccines for both human and animal use.
With the pandemic still ongoing, TRANSVAC2 is renewing its commitment to supporting academic and commercial vaccine developers through a new call for proposals dedicated to SARS-CoV-2 / COVID-19, with a special emphasis on variants of concern. Other project proposals will also be considered.
Services will be offered free of charge, with few exceptions. Academic and non-academic research groups, SMEs and industries can apply!
Are you a researcher? Do you have good preliminary results, but need support to further develop your vaccine candidate? TRANSVAC2 R&D services might be a perfect match for you!
The transnational access (TNA) call runs until May 31st, 2022. For further information on services available and how to apply please visit www.transvac.org/transvac2.
TRANSVAC2 is a European vaccine research and development (R&D) infrastructure project coordinated by the European Vaccine Initiative (EVI) and dedicated to accelerating the development of safe, effective and affordable vaccines.
TRANSVAC2 has received funding from the European Union’s Horizon 2020 research and innovation program under grant agreement N° 730964.